IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

(2020) Shaji K Kumar et al.   LANCET ONCOLOGY

Deciphering the chronology of copy number alterations in Multiple Myeloma

(2019) Anil Aktas Samur et al.   Blood Cancer Journal

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

(2018) Brian A. Walker et al.   BLOOD

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

(2018) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

The cellular origin and malignant transformation of Waldenstrom macroglobulinemia

(2015) B. Paiva et al.   BLOOD

Genetics of multiple myeloma: another heterogeneity level?

(2015) J. Corre et al.   BLOOD

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

(2013) M. Varettoni et al.   BLOOD

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

(2013) Z. R. Hunter et al.   BLOOD

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

(2013) B. A. Walker et al.   BLOOD

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities

(2012) Esteban Braggio et al.   MODERN PATHOLOGY

IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

(2010) Steven R. Schuster et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pathophysiology of Waldenstrom's macroglobulinemia

(2010) M. J. Stone et al.   HAEMATOLOGICA